MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study
This database analysis showed that the main type of MET mutation is amplification in malignant melanoma. MET-amplified solid tumors might be considered for targeted therapy, as MET amplification can be regarded as a risk factor affecting the prognosis of patients with tumors treated with immunotherapy.
Authors
- Lu Si (ORCID: https://orcid.org/0000-0002-2123-9761)
- Bin Lan
- Yu Chen
- Xiaojun Cai (ORCID: https://orcid.org/0000-0002-3399-3067)
- Huishan Zhang (ORCID: https://orcid.org/0000-0001-5324-9959)
- Yu-Fang Huang (ORCID: https://orcid.org/0000-0002-3832-1294)
- Ting Xu (ORCID: https://orcid.org/0000-0002-7851-3389)
- Xuefeng Wang (ORCID: https://orcid.org/0000-0002-9361-0398)
- Jing Lin (ORCID: https://orcid.org/0000-0002-9025-1721)
- Chuanben Chen (ORCID: https://orcid.org/0000-0002-5994-8897)
- Caili Li (ORCID: https://orcid.org/0000-0003-0967-6077)
- Shengjie Bai
Institutions
- Fujian Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Annoroad Gene Technology (China) (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1186/s12885-024-13163-z
- Citations
- 2
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Natural Science Foundation of Fujian Province
- Peking University
- Fujian Provincial Health Technology Project